ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on Wednesday reaffirmed its expectation to achieve cash-flow breakeven in 2027, even as no additional commercial formulary decisions for its epinephrine nasal spray Neffy were secured during the July 1, 2026 coverage cycle.
The company also lowered its projected 2026 operating expenses, citing tighter cost controls and prioritizing commercial investments.
No New Commercial Coverage Added In July Cycle
ARS Pharma said discussions with certain payers continued through mid-June, but recent feedback indicated that no new commercial formulary additions or coverage decisions for Neffy were made for the July 1 cycle.
Despite the lack of new commercial wins, the company said Neffy remains widely available to commercially insured patients through a combination of direct coverage and a recently introduced retail cash-pay option priced in line with other epinephrine products.
